Program in Pharmacogenomics and Precision Medicine
Information for Applicants
With the approval of its advisory council, starting in 2014 the National Institute of General Medical Sciences (NIGMS) will begin transitioning the Pharmacogenomics Research Network (PGRN ) from set-aside funding into the regular, competitive research pool. The intent is to support all research projects through investigator-initiated awards; cooperative agreements with staff roles will no longer be used for research activities. The Institute will continue to coordinate a network designed to promote investigations in pharmacogenomics and personalized medicine and will also continue to collaborate with the other NIH institutes and offices.
NIGMS is soliciting applications for a limited number of research centers (P50) and network resources (R24) as well as the knowledge base PharmGKB (R24) and a coordinating hub to support network functions (U24). New funding opportunity announcements (FOAs) were published in early 2014 with application due dates beginning in fall 2014. These FOAs are mostly program announcements with multiple receipt dates that are open for several years and will not have set-aside funds. Applications will be assigned by the NIH Center for Scientific Review (CSR) and reviewed by the NIH institutes and CSR according to standard receipt, referral and review guidelines.
Many NIH components actively support research in pharmacogenomics and related fields, and they routinely accept applications for R01s and P01s and some specialized programs. A partial list of funding opportunities is below. Potential applicants are encouraged to discuss their plans with staff members, who can aid in identifying the relevant programs. New FOAs will not be developed in areas where there are existing mechanisms, such as R01s, to apply for support.
All investigators with an interest in pharmacogenomics who are funded through these and other mechanisms may indicate a desire to participate in the network beginning in July 2015. Many network-wide functions will be based upon the existing PGRN and other successful models, and investigator input will be sought as the network is established.
Pharmacogenomics-Related Funding Opportunities
Research Centers for Pharmacogenomics in Precision Medicine (P50)
Enabling Resources for Pharmacogenomics (R24)
Pharmacogenomics Knowledge Base, PharmGKB (R24)
Administrative Coordination Hub for the PGRN (U24)
Program Project Grants (P01)
Collaborative Interdisciplinary Team Science in NIDDK Research Areas (R24)
NIH Clinical Trial Planning Grant Programs (R34)
Ancillary Studies to Ongoing Clinical Research Studies and Trials (R01)
Dissemination and Implementation Research in Health (R01)
Research Project Grant (Parent R01)
Rochelle M. Long, Ph.D.
Cashell E. Jaquish, Ph.D.
Weiniu Gan, Ph.D.
Pothur Srinivas, Ph.D.
Kelly Filipski, Ph.D.
Minkyung (Min) Song, Ph.D.
Kevin Walton, Ph.D.
Joni Rutter, Ph.D.
Aaron Pawlyk, Ph.D.
Simona Volpi, Ph.D.
Geetha Senthil, Ph.D.
Zhaoxia Ren, M.D., Ph.D.
Yan Wang, M.D., Ph.D.
Lisa Begg, Ph.D.